ICD-9-CM indicates International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision.
eMethods. Supplementary methods
eTable 1. ICD-codes for study variables
eTable 2. Reasons for censoring in Parkinson’s disease (PD) patients and referent subjects
eTable 3. Hazard ratios of suicide in Parkinson's disease (PD) patients compared to referent subjects from the general population
eTable 4. Hazard ratios of suicide in Parkinson's disease patients compared to referent subjects before and after adjusting for mental disorders
eTable 5. Hazard ratios of suicide in Parkinson's disease patients compared to referent subjects from the general population stratified by their characteristics
eTable 6. Comparisons between socio-demographic and clinical characteristics of suicide and non-suicide in Parkinson’s disease (PD) patient and referent subjects
eTable 7. Characteristics of Parkinson’s disease patients and referent subjects who died by suicide
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Chen Y, Yu S, Hu Y, et al. Risk of Suicide Among Patients With Parkinson Disease. JAMA Psychiatry. 2021;78(3):293–301. doi:10.1001/jamapsychiatry.2020.4001
Is Parkinson disease (PD) associated with an increased risk of suicide, and which characteristics (sociodemographic, clinical, and comorbid) are associated with suicide risk in PD?
In this large population-based cohort of patients with PD (n = 35 891) and matched control participants (n = 143 577) from Taiwan who were followed up over 11 years, the risk of suicide was significantly higher in patients with PD than control participants, after considering markers of socioeconomic position, medical comorbidities, dementia, and mental disorders, including depression. Suicide risk remained higher across the follow-up period.
Parkinson disease, a common neurodegenerative disorder in elderly persons, is associated with an increased risk of suicide that is not fully explained by higher rates of mental disorders in patients with PD.
Parkinson disease (PD) is an increasingly common neurodegenerative disorder in many aging societies. Although comorbidities with mental disorders are common in PD, whether PD is associated with an increased risk of suicide is unclear.
To use a large national representative PD cohort to compare the risk of suicide in patients with PD and control participants and identify potential risk factors.
Design, Setting, and Participants
This nationwide population-based cohort study used linked data from Taiwan’s National Health Insurance data set and Taiwan Death Registry between January 2002 and December 2016. Patients with incident PD diagnosed between January 2005 and December 2014 were followed up until December 2016. Four control participants from the general population were randomly selected by risk set sampling and were matched on age, sex, and residence to each affected individual. Data analysis occurred from June 2019 to October 2020.
Diagnosis of PD retrieved from the National Health Insurance data set.
Main Outcomes and Measures
Suicide was recorded in the Taiwan Death Registry. Cox proportional models and hazard ratios (HRs) were used to estimate the association between PD and the risk of suicide over the follow-up period.
Over 11 years, 35 891 patients with PD were followed up (17 482 women [48.7%]; mean [SD] age, 72.5 [10.1] years) and matched to 143 557 control participants (69 928 women [48.7%]; mean [SD] age, 72.5 [10.1] years). A total of 151 patients with PD (cumulative incidence, 66.6 per 100 000 [95% confidence limits [CL], 78.1-91.7]) and 300 control participants (cumulative incidence, 32.3 per 100 000 [95% CL, 36.2-40.5]) died by suicide. The risk of suicide was higher (HR, 2.1 [95% CL, 1.7-2.5]) in patients with PD than control participants, after adjustment for markers of socioeconomic position, medical comorbidities, and dementia. After controlling for mental disorders, the association between PD and suicide risk remained (HR, 1.9 [95% CL, 1.6-2.3]). Compared with control participants who died by suicide, those who died by suicide in the PD group were slightly younger (mean [SD] age: patients with PD, 74.0 [10.4] years vs control participants, 76.0 [10.2] years; P = .05) and more likely to be urban dwelling (medium urbanization, 39 patients with PD [25.8%] vs 115 control participants [38.3%]; high urbanization, 84 patients with PD [55.6%] vs 136 control participants [45.3%]; P = .03), have mental disorders (depression, 15 of 151 patients with PD [9.9%] vs 15 of 300 control participants [5.0%]; other mental disorders, 12 patients with PD [8.0%] vs 11 control participants [3.7%]; P = .02), and adopt jumping as a method of suicide (21 patients with PD [13.9%] vs 16 control participants [5.3%]; P < .01).
Conclusions and Relevance
In this population-based cohort study, Parkinson disease, a common neurodegenerative disorder common in elderly persons, was independently associated with an increased risk of suicide. Integrating mental health care into primary care and PD specialty care, along with socioenvironmental interventions, may help decrease the risk of suicide in patients with PD.
Older adults are at a greater suicide risk than other age groups globally.1 Paralleling trends in rapid population aging, a rise in the number of suicides is expected over the next decades. Efforts targeting older age groups to reduce their suicide burden are crucial.
Parkinson disease (PD) is a progressive neurodegenerative disorder; the prevalence increases with age.2,3 Parkinson disease is the second most prevalent neurodegenerative disorder after Alzheimer disease.4 In addition to motor symptoms, psychiatric symptoms, such as depression and anxiety, are common over the course of PD.5 Approximately 40% to 50% of patients with PD are affected by depression,5,6 and 30% to 40% are affected by anxiety disorders.7,8 In addition to the long-established associations between mental disorders and suicide,9 the physical limitations caused by PD and the well-known increased risk of suicide in older persons call for attention to the likelihood of suicide in patients with PD.
Research into the association between PD and suicide has not provided a consistent picture.10 Several studies have found high suicide rates in patients with PD,11-17 whereas others have not,18-20 and 1 study21 has shown a considerably lower risk than in the general population. Given that suicide is a rare occurrence, studies with large and representative population-based PD samples are needed to reach a reliable estimate of suicide rates. Parkinson disease causes progressive physical disability, which is an important suicide risk factor in younger and middle-aged populations; whether PD is associated with elevated suicide risk is understudied.22
Over and above the estimation of suicide risk in PD using a large national representative PD cohort within Taiwan’s National Health Insurance (NHI) system, we assessed a plethora of factors possibly associated with suicide risk in PD. We explored (1) differences in characteristics (sociodemographic attributes, medical and mental disorders, and methods of suicide) of patients with PD and control participants from the general population who died by suicide and (2) factors associated with suicide risk (disease duration, PD severity, medical and mental comorbidities) in patients with PD.
This study is a population-based cohort nested within Taiwan’s NHI data set provided by the Health and Welfare Data Science Center between 2002 and 2016. A universal NHI program has been implemented in Taiwan since March 1995; currently, more than 99% of the Taiwanese population is enrolled in the NHI program.23 Many studies evaluated the validity of diagnostic codes in the NHI data set, and validation studies showed modest to high sensitivity, depending on the disease.24 This study was exempted from informed consent because the analysis was of secondary data, and the study was approved by the Research Ethics Committee of the Taipei City Hospital.
The criteria used to identify incident patients with PD in the current study were validated previously.25 The Figure presents a flowchart for the selection of patients with PD. Detailed sample selection criteria are provided in the eMethods in the Supplement. We retained for our analyses patients with incident PD diagnosed between January 2005 and December 2014. For those with PD, the index date is the date of first inpatient or outpatient record for PD after January 2005.
We used risk set sampling to match 4 control participants from the general population to each individual with PD on age, sex, year of PD diagnosis, and county of residence at the index date of the PD case. Control participants were alive and free of PD at the index date. If control participants developed PD over the study period, they were censored at the diagnosis date and included as patients with PD and followed up after the diagnosis date. Within each matched set, control participants were assigned to have the same index date as the matched individual with PD.
The outcome variable was suicide, ascertained through linking the unique National Identification Numbers of study participants to the Taiwan Death Registry during 2005 and 2016. Codes from the International Classification of Diseases, Ninth Revision, Clinical Modification and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) used to identify suicides, and methods of suicide are listed in eTable 1 in the Supplement.26
We evaluated whether dementia, depression, and mental disorders other than depression contributed to suicide risk. Dementia was defined by a list of ICD codes previously determined.27 Mental disorders were defined as receiving a primary diagnosis of mental disorder in at least 3 outpatient visits or 1 inpatient care incident, within 1 year prior to the incidence of PD or after the onset of PD. In the current analysis, we defined mental disorders as mental and behavioral disorders other than organic mental disorders (eg, PD, Alzheimer dementia). Dementia, depression, and other mental disorders over the follow-up were defined as time-dependent variables. The ICD codes used to ascertain the study variables are listed in eTable 1 in the Supplement.
Insurance premium and urbanization at baseline were selected as proxy measures of socioeconomic position (SEP). Insurance premium was based on enrollees’ monthly insurance payment: $0 to $36, more than $36 to $650, or more than $650. Urbanization index was categorized into 3 groups: high (metropolitan cities), medium (small cities and suburban areas), and low (rural areas).28,29 The Charlson Comorbidity Index at baseline, a widely used indicator of medical comorbidities, was used to represent physical conditions.21
Disease duration was defined as a time-dependent variable and was categorized as less than 1 year, 1 to 3 years, and 4 or more years. Severity of PD over the follow-up period was modeled as a time-dependent variable based on the annual cumulative levodopa-equivalent dose for levodopa, dopamine agonists, and other PD medications (low, <33rd percentile; moderate, 33rd–<66th percentile; high, ≥66th percentile) after the index date.30,31
Patients with PD and control participants were followed up until the end of 2016, the last date of presence in the NHI system, or death from any cause, whichever occurred first; in addition, patients with PD who received deep brain stimulation were censored as of the date of surgery. Reasons for censoring are described in eTable 2 in the Supplement. We used the Cox proportional risk model to estimate hazard ratios (HRs) and their 95% confidence limits (CLs) with time since index date as the time scale. The proportional hazard assumption was verified using plots of log (−log[survival function]) as a function of time and by including in the models interactions term between covariates and log(time). A series of Cox models by including covariates were fitted sequentially. A Fine and Gray competing risk model32 was fitted to compare the cumulative incidence of suicide in association with PD after considering risk of death from other causes. We report the cumulative incidence of suicide by PD status estimated from the cumulative incidence function while taking into account competing causes of death. We also compared differences in demographic and clinical characteristics between suicide and nonsuicide outcomes in patients with PD and control participants. In analyses restricted to patients with PD, we used Cox models to assess whether clinical characteristics, including disease duration, severity, and medical or mental comorbidities contributed to the risk of suicide.
Data analyses were completed from June 2019 to October 2020 with SAS version 9.4 (SAS Institute). The significant threshold was set at 2-tailed P ≤ .05 level.
A total of 35 891 patients with PD (18 409 men and 17 482 women; mean [SD] age, 72.5 [10.1] years) were included. They were matched to 143 557 control participants (73 629 men and 69 928 women; mean [SD] age, 72.5 [10.1] years) from the general population. The median follow-up was 4.95 years (mean [SD], 5.38 [2.77] years) for patients with PD and 5.40 years (mean [SD], 5.78 [2.86] years) for control participants.
Over the follow-up, 151 patients with PD (93 men and 58 women) and 300 control participants (197 men and 103 women) died by suicide. The cumulative incidence of suicide was higher in patients with PD than control participants throughout the follow-up. In individuals with PD, the 11-year cumulative incidence of suicide was 66.6 per 100 000 (95% CL, 78.1-91.7 per 100 000); in control participants, cumulative incidence was 32.3 per 100 000 (95% CL, 36.2-40.5 per 100 000).
At baseline (Table 1), patients with PD were more likely to have physical and mental comorbidities (1 medical comorbidity, 9068 of 35 891 patients with PD [25.3%] vs 25 658 of 143 557 control participants [17.9%]; 2 or more medical comorbidities, 6858 patients with PD [19.1%] vs 20 997 control participants [14.6%]). The prevalence of depression (1269 patients with PD [3.5%] vs 1631 control participants [1.1%]) and mental disorders other than depression (1378 [3.8%] vs 2087 [1.5%]) was higher in patients with PD than control participants.
The risk of suicide in patients with PD was about 2 times higher than in the control group after adjustment for matching variables, SEP, medical comorbidities, dementia, and mental disorders (hazard ratio [HR], 1.9 [95% CL, 1.6-2.3]) (Table 2). The results for sequential modeling are provided in eTable 3 in the Supplement. The HR of suicide in the null model (ie, the model adjusted for matching variables only) was 2.2 (95% CL, 1.8-2.7) (eTable 3 in the Supplement). Adjustment for mental disorders (model 5) had the strongest result, leading to an attenuation of approximately 14% (HR, 1.9 [95% CL, 1.5-2.3]). An additional analysis that categorized mental disorders into schizophrenia, bipolar disorder, depression, and other mental disorders yielded similar conclusions (eTable 4 in the Supplement). In stratified analyses, the association between PD and suicide was present in all strata defined by sex, age, insurance premium, urbanization, and mental disorders; the number of patients with dementia was too small to obtain an estimate in that group (eTable 5 in the Supplement).
Differences between participants who died by suicide and those who did not are presented in eTable 6 in the Supplement by PD status. Patients with PD who died by suicide were less likely to have dementia (11 of 151 who died by suicide [7.3%] vs 5840 of 35 740 who did not die by suicide [16.3%]; P = .003), more likely to be men (93 of 151 [61.6%] vs 18 316 of 35 740 [51.3%]; P = .01), and more likely to have mental disorders (depression, 15 [9.9%] vs 1254 [3.5%]; other mental disorders, 12 [8.0%] vs 1366 [3.8%]; P < .001). Similar to the observations from the general population, control participants who died by suicide were more likely to be men (197 of 300 who died by suicide [65.7%] vs 73 432 of 143 257 who did not die by suicide [51.3%]), be in lower SEPs (monthly insurance premiums: $0-36, 71 [23.7%] vs 20 192 [14.1%]; >$36-$650, 85 [28.3%] vs 36 970 [25.8%]; >$650, 144 [48.0%] vs 86 095 [60.1%]; P < .001; urbanization: low, 49 [16.3%] vs 21 654 [15.1%]; medium, 11 [38.3%] vs 45 716 [31.9%]; high, 13 [45.3%] vs 75 887 [53.0%]; P = .02), and have mental disorders (depression, 15 [5.0%] vs 1616 [1.1%]; other mental disorders, 11 [3.7%] vs 2076 [1.5%]; P < .001).33
Table 3 shows analyses restricted to patients with PD to assess clinical characteristics associated with the risk of suicide in PD. Disease duration was not associated with the risk of suicide. Compared with those who did not receive levodopa, elevated risks of suicide were found in those who were prescribed low doses (HR, 1.6 [95% CL, 1.0-2.6]; P = .05) or moderate doses (HR, 1.9 [95% CL, 1.2-3.1]; P = .01) but not high doses; there was no association with dopamine agonists and other drugs. Depression was associated with a 3-fold increased risk of suicide compared with patients with PD without depression (HR, 3.3 [95% CL, 1.9-5.8]; P < .001). Dementia was no longer associated with suicide risk in patients with PD in the models adjusting for covariates.
The characteristics of patients with PD and control participants who died by suicide were compared (eTable 7 in the Supplement). Patients with PD who died by suicide were younger (mean [SD] age: patients with PD, 74.0 [10.4] years vs control participants, 76.0 [10.2] years; P = .05), had higher rates of mental disorders (depression, 15 of 151 patients with PD [9.9%] vs 15 of 300 control participants [5.0%]; other mental disorders, 12 patients with PD [8.0%] vs 11 control participants [3.7%]; P = .02), were more likely to reside in urban areas (medium urbanization, 39 [25.8%] vs 115 [38.3%]; high urbanization, 84 [55.6%] vs 136 [45.3%]; P = .03), and were more likely to adopt jumping as a method of suicide (21 [13.9%] vs 16 [5.3%]; P < .01).
In a large national representative population-based cohort, suicide risk was about 2 times higher in patients with PD than the general population, after adjustment for markers of SEP, medical comorbidities, dementia, and mental disorders. The suicide risk elevation in PD was only partially explained by comorbidity with depression and other mental disorders. Parkinson disease in itself markedly escalated the risk of suicide.
Among those who died by suicide, those with PD were somewhat different from the comparison group; they were younger, were more likely to have a diagnosis of mental disorder, resided more often in urban areas, and were more likely to have died by jumping. In patients with PD, risk factors of suicide included low to moderate disease severity and mental disorders, including depression. Disease duration and comorbidity with dementia and medical diseases did not affect suicide risk in patients with PD.
Although the existing literature is often inconsistent, there is evidence in favor of an increased risk of suicide in PD.11,14-16 Our estimate of a 2-fold increased risk is close to reports from Denmark in 2015 (men: HR, 1.92 [95% CI, 1.26-2.92]; women: HR, 2.26 [95% CI, 1.25-4.08]) and 2020 (HR, 1.7 [95% CI, 1.5-1.9]),14,34 the UK (adjusted odds ratio, 2.41 [95% CI, 1.15-5.07]),13 and a general hospital sample from Seoul, South Korea (HR, 1.99 [95% CI, 1.33-2.85])12; it was lower than the association estimate from a nationwide population-based cohort from South Korea (HR, 4.73), but this HR had a very wide confidence interval (95% CI, 0.99-11.20).11
Several mechanisms may explain the link between PD and suicide. First, being diagnosed with PD may constitute an acute life event, which is a prominent risk factor of suicide.35 Second, depression, the most prominent risk factor of suicide, is a common nonmotor symptom in PD.5,6,35 We confirmed a prominent direct effect of PD on the risk of suicide, but depression and other mental disorders also played a role. Third, functional decline, a common feature of PD, has been suggested to be an important contributing factor for suicide in elderly persons.36 Functional impairments may lead to disability, dependence, and feelings of perceived burdensomeness and disconnectedness from social networks; these are all risk factors of suicide in late life.36 Finally, suicide risk in PD may be emerge with treatment. Although inconsistent, some studies reported an association between dopaminergic agents and suicide in PD,12 whereas other studies did not support this association.37 We did not find evidence in favor of a strong association between use of dopamine agonists and suicide in patients with PD. Furthermore, some reports suggest an increased risk of suicide and suicide attempt in patients with PD and subthalamic nucleus stimulation,38,39 but whether the link is causal or confounded by disease severity remains unclear. To eliminate the influence of subthalamic nucleus stimulation, patients with PD who underwent deep brain stimulation were treated as censored in observations after surgery.
We did not locate any previous study that had prospectively followed patients with PD over a long period to examine a plethora of risk factors associated with suicide. In this PD cohort, we found that the suicide risk elevation was constant and persistent over time. We did not identify any particular high-risk or low-risk period. Unlike suicide patterns generally observed in Alzheimer disease, namely an initial high risk that decreases subsequently and is lower than the general population at advanced stages,34,40,41 we observed a persistent elevated suicide risk in PD, as a Danish study had.34 Regarding PD severity, we did not have direct information and used the dosage of antiparkinsonian drugs as a surrogate; patients who did not require levodopa probably had fewer symptoms and had significantly lower suicide risk compared with those who had low to moderate symptoms. Those who were prescribed with higher dosages of levodopa may have more severe cognitive and motor function decline and thus were less capable of conducting suicidal acts; alternatively, they may have adapted to their disabilities.
Late-life suicide rates are particularly high in many East Asian countries; the suicide rate ratio of elderly individuals (≥65 years old) to the general population ranges between 3 and 4 to 1.33,42 This finding is in contrast with ratios slightly higher than 1 reported in Western countries.33,42 In Taiwan, suicide rates of those of older ages (≥65 years old) were between 31.2 and 39.3 per 100 000 population during the study period (2002-2016),43 similar to our estimated suicide incidence rate in control participants (32.3 per 100 000 population). The corresponding age-standardized general population suicide rates were in the range of 11.8 to 16.8 (ie, less than half of the rates in elderly individuals). These figures suggest that high suicide rates in elderly adults is an important public health concern in Taiwan.
In Taiwan, similar to many East Asian countries, veneration of older age groups is a fundamental cultural value.44 However, rapid industrialization and weakening of traditional family networks may have resulted in paradoxically high suicide rates in elderly individuals.33,45 Elders’ expectations of living with their children are crushed as an increasing number of younger age groups live under nuclear family setups. Their progressive disability combined with disappointment toward their children may foster suicidality in patients with PD. Prevention efforts directed toward increasing family and community connectedness is preeminent.
The debilitating nature and high rates of co-occurring mental disorders in PD may explain the findings that those with PD who died by suicide were younger and more likely to have received a diagnosis of mental disorder. We found that patients with PD who died by suicide were more likely to reside in urban areas and more often adopted jumping as a method of suicide. This is consistent with previous research showing that jumping from a home is a common way of death in older adults with frailty who are dwelling in high-rise buildings in urban areas.46-49 In fact, for patients with PD and a high risk of suicide (eg, comorbidity with mental disorders), a jump from their own residential buildings can be easy and readily accessible. Hence, home safety assessments should be an integrated part of suicide prevention measures for patients with PD at high risk.
The strengths of the current study lie in its large and representative sample with a cohort design. In addition, it had a long follow-up.
However, several limitations should be acknowledged. First, the covariates that we assessed were limited by data availability from the data set. Information such as lifestyle behaviors, ethnicity, detailed disease history, and disease staging was not available. Second, we relied on physician-recorded diagnosis in medical claim data; hence, potential disease misclassification may be present. Nonetheless, the methods used to ascertain patients with PD were validated previously.25 Third, the prevalence of depression (1.1%) in the general population comparison group was approximately the same as the estimate from a nationwide epidemiological survey (1.2%).50 The low rate of depression found in our study is likely to be attributable to cultural factors or mental illness stigma that lead to underdiagnosis of depression in many Chinese societies,51 rather than disease ascertainment in the present study. Lastly, although Taiwan’s death records data are considered fairly reliable,52 underreporting and misclassification are more common for suicides than other causes of death.1,26 Based on previous research,1,26 undetermined intent was included in the analyses of suicides to reduce potential underreporting.
Taking advantage of a large and representative PD cohort with 11 years of follow-up, we found that suicide was about 2 times more frequent in patients with PD than in the general population. Although comorbidity with mental disorders contributed partially to their suicide risk elevations, PD in itself was a potent determinant of suicide. Over and above identifying and treating mental disorders in PD, integrating mental health care into primary care, geriatric health care, and PD specialty care might be helpful. Furthermore, socioenvironmental interventions, such as enhancing family and community connectedness and home safety assessment to prevent suicide by jumping, are all potential intervention measures.
High suicide rates among elderly individuals represent a growing concern in many developed countries worldwide. Future studies should explore factors that have not been examined in the current study to better understand the high suicide risk in PD.
Accepted for Publication: October 23, 2020.
Published Online: December 16, 2020. doi:10.1001/jamapsychiatry.2020.4001
Corresponding Author: Pei-Chen Lee, PhD, Department of Health Care Management, National Taipei University of Nursing and Health Sciences, 89, Nei-Chiang Street, Wan-Hua District, Taipei 10845, Taiwan (firstname.lastname@example.org).
Author Contributions: Dr Lee had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Chen, Sun, Li, Elbaz, Lee.
Acquisition, analysis, or interpretation of data: Chen, Sun, Hu, Artaud, Carcaillon-Bentata, Elbaz, Lee.
Drafting of the manuscript: Chen, Sun, Lee.
Critical revision of the manuscript for important intellectual content: Hu, Li, Artaud, Carcaillon-Bentata, Elbaz, Lee.
Statistical analysis: Hu, Li, Artaud, Elbaz.
Obtained funding: Chen, Lee.
Administrative, technical, or material support: Sun, Lee.
Conflict of Interest Disclosures: None reported.
Funding/Support: Dr Chen is supported by the National Health Research Institutes (grant NHRI-EX109-10818PI), the Taiwan Ministry of Science and Technology (MOST grant 108-2314-B-532-007-MY2) and the Department of Health, Taipei City Government (grant 10801-62-019). Dr Lee is supported in part by the Taiwan Ministry of Science and Technology (MOST grant 107-2314-B-227-009-MY3) and the Taipei City Hospital (grant 10901-62-014).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Information: Data source: Health and Welfare Data Science Center.